This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Oxybutynin

Read time: 1 mins
Marketing start date: 23 Nov 2024
...
 

Summary of product characteristics


Effective Time

20221031

Version

6

Spl Product Data Elements

oxybutynin oxybutynin OXYBUTYNIN CHLORIDE OXYBUTYNIN ALGINIC ACID HYDROGENATED CASTOR OIL HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE METHACRYLIC ACID CELLULOSE, MICROCRYSTALLINE POVIDONE TALC TRIETHYL CITRATE WHITE TO OFF-WHITE ROUND 255 oxybutynin oxybutynin OXYBUTYNIN CHLORIDE OXYBUTYNIN ALGINIC ACID HYDROGENATED CASTOR OIL HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE METHACRYLIC ACID CELLULOSE, MICROCRYSTALLINE POVIDONE TALC TRIETHYL CITRATE WHITE TO OFF-WHITE ROUND 256 oxybutynin oxybutynin OXYBUTYNIN CHLORIDE OXYBUTYNIN ALGINIC ACID HYDROGENATED CASTOR OIL HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE METHACRYLIC ACID CELLULOSE, MICROCRYSTALLINE POVIDONE TALC TRIETHYL CITRATE WHITE TO OFF-WHITE ROUND 257

Application Number

ANDA202332

Brand Name

Oxybutynin

Generic Name

oxybutynin

Product Ndc

70771-1086

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Oxybutynin chloride extended-release tablets USP, 5 mg NDC 70771-1086-3 30 tablets Rx only Oxybutynin chloride extended-release tablets USP, 10 mg NDC 70771-1087-3 30 tablets Rx only Oxybutynin chloride extended-release tablets USP, 15 mg NDC 70771-1088-3 30 tablets Rx only Oxybutynin chloride extended-release tablets Oxybutynin chloride extended-release tablets Oxybutynin chloride extended-release tablets

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.